S. V. Alekseeva

S. V. Alekseeva

Auto-generated profile, based on publicly available information

S. V. Alekseeva

Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2019 in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
Verified
Journal Article
Open access
PDF file
ASA. V. Sorokina
A. V. Sorokina
SAS. V. Alekseeva
S. V. Alekseeva
NEN. V. Eremina
N. V. Eremina
ADA. D. Durnev
A. D. Durnev
Preclinical safety evaluation is an important stage in the development of medicinal products. Clinical laboratory studies, including haematological, biochemical and pathomorphological studies, are an essential part of chronic toxicity studies. A careful choice of methodological approaches to examination of toxicological characteristics of drug candidates makes it possible to assess the degree of risk associated with their subsequent clinical use, identify potential target organs, determine the extent of damage, as well as the possibility and dynamics of restoring damaged systems. Key prerequisites for obtaining adequate results of the studies are correct methodological implementation of all the stages of sample preparation and careful consideration of all factors during interpretation of the obtained data. Thus, the choice of methodological approaches to blood tests is often determined by the species, age and sex of laboratory animals, as well as by specific characteristics of the tested drug. The aim of the study was to summarise data on haematological studies performed in the Drug Toxicology Laboratory of the Federal State Budgetary Institute «Zakusov Institute of Pharmacology» when conducting chronic toxicity studies.

1 March 2022 in Moscow University Biological Sciences Bulletin
Verified
Journal Article
Closed access
PDF file
AVA. G. Vasilchuk
A. G. Vasilchuk
EIE. A. Ivanova
E. A. Ivanova
AMA. I. Matyushkin
A. I. Matyushkin
SAS. V. Alekseeva
S. V. Alekseeva
KKK. S. Kachalov
K. S. Kachalov
TVT. A. Voronina
T. A. Voronina
The effect on blood pressure (BP), hematological indices, and body weight of rats was evaluated for nonselective cyclooxygenase (COX) inhibitor diclofenac

30 April 2023 in Voprosy onkologii
Verified
Journal Article
Open access
PDF file
РЖРуслан Журиков
Руслан Журиков
ЛКЛариса Коваленко
Лариса Коваленко
САСветлана Алексеева
Светлана Алексеева
СНСергей Никитин
Сергей Никитин
АДАндрей Дурнев
Андрей Дурнев
Introduction. The combined use of cytostatic agents with drugs from other groups is a promising method for reducing hematotoxicity. Aim. To evaluate the impact of 5-hydroxypyrimidine derivatives and gemcitabine, as well as their combinations, on tumor growth inhibition, survival, and hematological parameters in animals with Ca755 adenocarcinoma. Materials and methods. After inoculation of adenocarcinoma Ca755 mice received SNK-411, SNK-578, gemcitabine or their combination from 2nd to 15th day of tumor development. Tumor volume was measured and tumor growth inhibition was calculated on the 9th, 16th and 21st days of tumor development. On the 22nd day, half of the animals were left for follow-up and evaluation of survival, while the other half was euthanized, and their blood samples were taken for analysis. Results. Compared to the intact control, a decrease in hemoglobin and erythrocyte levels was observed in all experimental active control groups that received SNK-411, SNK-578, and gemcitabine. The administration of 5-hydroxypyrimidine derivatives in combination with gemcitabine prevented the suppression of hematopoiesis. No statistically significant differences were found in platelet and leukocyte counts among the groups. Tumor growth inhibition (TGI) was studied on 7th day after the 14-day administration of SNK-411. In the group that received SNK-411 TGI was 45 %, in the group that received SNK-578 — 53%, in the group treated by gemcitabine — 61 %. 14-day combined administration of SNK-411 and gemcitabine resulted in 79 % TGI. Combination of SNK-578 and gemcitabine inhibited tumor growth by 80 %. Gemcitabine increased median survival time (MST) by 44 %, SNK-411 — by 18 %, SNK-578 — by 21 %. Combinations of SNK-411 and gemcitabine increased MST by 62 %, SNK-578 and gemcitabine — by 71 %. Conclusion. The combination of gemcitabine and 5-hydroxypyrimidine derivatives demonstrated prominent antitumor effect without hematotoxicity. Введение. Совместное применение цитостатиков с лекарственными препаратами из других групп является перспективным методом снижения гематотоксичности. Цель. Оценить влияние производных 5-оксипиримидина и гемцитабина, а также их комбинаций на торможение роста опухоли, выживаемость и гематологические показатели животных с аденокарциномой Ca755. Материалы и методы. Мыши линии C57BL после инокуляции аденокарциномы Ca755 получали СНК-411, СНК-578, гемцитабин или их комбинации со 2-го по 15-ый день развития опухоли. На 9, 16 и 21 день развития опухоли измеряли объем и рассчитывали торможение роста опухоли. На 22-ой день половину животных отсадили для исследования выживаемости, вторую половину животных вывели из эксперимента и взяли кровь для анализа. Результаты. В экспериментальных группах активного контроля и при введении СНК-411, СНК-578 и гемцитабина отмечено снижение содержания гемоглобина и эритроцитов по сравнению с интактным контролем. Введение производных 5-оксипиримидина совместно с гемцитабином препятствовало угнетению кроветворения. Различия содержания тромбоцитов не выходили за пределы референсных значений. В межгрупповых показателях лейкоцитарной формулы не было выявлено значимых различий. Через 7 дней после 14-ти дневного введения СНК-411 торможение роста опухоли (ТРО) составило 45 %, у СНК-578 ТРО составило 53 %, введение гемцитабина вызывало торможение роста опухоли на 61 %. При курсовом введении СНК-411 совместно с двукратным введением гемцитабина ТРО составило 79 %. Совместное введение СНК-578 с гемцитабином вызывало торможение роста опухоли на 80 %. Увеличение продолжительности жизни (УПЖ) при введении гемцитабина составило 44 %, при введении СНК-411 — 18 %, при введении СНК-578 — 21 %. Совместное введение гемцитабина с СНК-411 вызывало увеличение продолжительности жизни на 62 %, сочетание введения СНК-578 с гемцитабином — на 71 %. Заключение. Комбинация гемцитабина с производными 5-оксипиримидина позволила получить выраженный противоопухолевый эффект без проявлений гематотоксичности.

3 December 2019 in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
Verified
Journal Article
Open access
PDF file
ASA. V. Sorokina
A. V. Sorokina
SAS. V. Alekseeva
S. V. Alekseeva
NEN. V. Eremina
N. V. Eremina
ADA. D. Durnev
A. D. Durnev
Chronic toxicity studies are an integral part of the overall toxicological evaluation of drug candidates. Biochemical studies of blood and urine serve to describe the general picture of the animal’s condition and to trace the dynamics of laboratory markers of organ damage after repeated administration of the drug — both for a group of animals, as well as individually. Pathomorphological studies of organs and tissues make it possible to understand the nature of damage at the cellular level. A systemic analysis of the data obtained allows for accurate identification of the body systems that are most susceptible to the toxic effect of the drug, as well as for assessment of the degree of impact and the reversibility of effects. Considering the great importance of the obtained pharmacological information, it is necessary to pay special attention to proper methodological implementation of all the stages of preparation and performance of the mentioned studies, as well as to proper analysis and interpretation of the data. The aim of the paper was to summarise the methodology of biochemical and pathomorphological studies based on the experience obtained in the Drug Toxicology Laboratory of the Federal State Budgetary Institute «Zakusov Institute of Pharmacology» when conducting chronic toxicity studies.

19 May 2023 in Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Open access
PDF file
ASA. V. Sorokina
A. V. Sorokina
SAS. V. Alekseeva
S. V. Alekseeva
IMI. A. Miroshkina
I. A. Miroshkina
AVA. V. Volkova
A. V. Volkova
KKK. S. Kachalov
K. S. Kachalov
ADA. D. Durnev
A. D. Durnev
Relevance. Assay of acute toxicity is a mandatory step in a preclinical safety study of medicines and pharmaceutical substances. The purpose of this study was to determine the parameters of acute toxicity of the substance GIZH-298. Methods. GIZH-298 was administered once orally to outbred mice of both sexes at doses of 350–550 mg/kg. Control mice received 0.5 ml of 1 % starch solution under the same conditions. During the experiment, the death of animals, signs of intoxication were observed, and the clinical picture was recorded. Pathological anatomical autopsy of the dead mice was performed as they died. Surviving mice were autopsied 14 days after the start of the experiment, immediately after their euthanasia. Results. The average lethal doses of the GIZh-298 substance when administered orally to mice were determined: LD50 in females was 356 mg/kg, LD50 in males was 438 mg/kg. Conclusion. Compound GIZH-298 for oral administration according to the classification of Sidorov K.K. (1973) is a moderately toxic substance and can be assigned to the 3rd class of toxicity, and in accordance with GOST 12.1.007-76 — to the 3rd hazard class.

25 June 2021 in Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Open access
PDF file
IMI. A. Miroshkina
I. A. Miroshkina
ASA. V. Sorokina
A. V. Sorokina
AVA. V. Volkova
A. V. Volkova
VZV. V. Zabrodina
V. V. Zabrodina
IAI. V. Alekseev
I. V. Alekseev
SAS. V. Alekseeva
S. V. Alekseeva
Assessment of acute toxicity is a necessary stage of preclinical research of the substance GIZh-298. The aim of present research is study of acute toxicity GIZh-298. Methods. GIZh-298 was administered once intraperitoneally to mice at doses 200-330 mg/kg. Equivalent volume of 1 % starch solution was administered to animals of the control groups. Periods of intoxication and death of animals with a detailed description of the observed clinical picture were registered. Euthanasia and pathoanatomical dissection were performed 14 days after drug administration. Results. The median lethal doses were identified: LD50 = 299,6 (279,7 – 320,8) mg/kg in female mice, LD50 = 302,3 (281,5 – 324,6) mg/kg in male mice at intraperitoneal introduction. The morphological view of the internal organs, detected during pathoanatomical dissection of all surviving experimental animals, did not differ from that observed in control animals. Conclusion. It was determined that GIZh-298 at intraperitoneal introduction concerns to low-toxic substances. According to classification Sidorov K.K. GIZh-298 may be related to 4th toxicity class.